首页 > 最新文献

Acta Psychiatrica Scandinavica最新文献

英文 中文
Augmentation with prazosin for patients with depression and a history of trauma: A randomised, double-blind, placebo-controlled study. 哌唑嗪对有创伤史的抑郁症患者的辅助治疗:随机、双盲、安慰剂对照研究。
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-09-27 DOI: 10.1111/acps.13763
Ping Guo, Yong Xu, Liang Lv, Min Feng, Yu Fang, Shanfei Cheng, Xiaoqing Xiao, Juanjuan Huang, Wei Sheng, Shikai Wang, Huanxin Chen

Introduction: Depression with a history of trauma often responds poorly to conventional antidepressants and has a poor prognosis. Prazosin, an α1-adrenoceptor blocker, has shown promise in treating post-traumatic stress disorder symptoms, particularly nightmares. Its potential in treating depression with trauma history warrants investigation.

Aims of the study: This randomised, double-blind, placebo-controlled study aimed to investigate the efficacy and tolerability of low-dose prazosin (0.5-1 mg/day) as an augmentation strategy in patients with depression and a history of trauma. We sought to determine if prazosin could provide rapid symptom improvement and enhance overall treatment response compared to placebo in this difficult-to-treat patient population.

Methods: This randomised, double-blind, placebo-controlled clinical study included 59 patients with first-episode or recurrent unipolar or bipolar depression. After basic antidepressant treatment, they were randomly assigned to a prazosin (0.5-1 mg/day) or placebo group for a 6-week double-blind controlled study. The Montgomery-Åsberg Depression Rating Scale, 17-item Hamilton Depression Scale (HAMD-17), and Hamilton Anxiety Scale (HAMA) were used to evaluate efficacy.

Results: There were no significant differences in the results of the demographic and clinical symptom assessment between the two groups (p > 0.05). The difference between the HAMD-17 and HAMA scores was statistically significant after 3 days of treatment (p < 0.05). The difference in response rate between the two groups was statistically significant after week 4 of treatment (end of week 4, 56.7% vs. 24.1%, p = 0.011; end of week 6, 80.0% vs. 48.3%, p = 0.011). The incidence of adverse reactions in the prazosin and placebo groups was 20.0% and 24.1%, respectively, with no statistically significant differences (p > 0.05); however, the prazosin group had a lower incidence of sleeplessness or nightmares (3.3% vs. 20.7%, p = 0.039) but a higher incidence of orthostatic hypotension (16.7% vs. 0%, p = 0.007). The severity of orthostatic hypotension was mild to moderate.

Conclusion: Low-dose prazosin can effectively improve the emotional symptoms of patients with depression and a history of trauma, and the common adverse reaction is mild-to-moderate orthostatic hypotension.

Clinical trial registration: ChiCTR2200063642.

简介有创伤史的抑郁症患者对传统抗抑郁药的反应通常很差,预后也很差。哌唑嗪是一种α1-肾上腺素受体阻滞剂,在治疗创伤后应激障碍症状(尤其是噩梦)方面显示出良好的前景。它在治疗有创伤史的抑郁症方面的潜力值得研究:这项随机、双盲、安慰剂对照研究旨在调查小剂量哌唑嗪(0.5-1 毫克/天)作为抑郁症和创伤史患者的增强策略的疗效和耐受性。我们试图确定,与安慰剂相比,哌唑嗪能否在这一难以治疗的患者群体中迅速改善症状并提高总体治疗反应:这项随机、双盲、安慰剂对照临床研究纳入了59名首次发病或复发的单相或双相抑郁症患者。经过基本抗抑郁治疗后,他们被随机分配到哌唑嗪(0.5-1毫克/天)或安慰剂组,进行为期6周的双盲对照研究。研究采用蒙哥马利-奥斯伯格抑郁评定量表、17项汉密尔顿抑郁量表(HAMD-17)和汉密尔顿焦虑量表(HAMA)来评估疗效:结果:两组患者的人口统计学和临床症状评估结果无明显差异(P>0.05)。治疗3天后,HAMD-17和HAMA评分之间的差异有统计学意义(P 0.05);然而,哌唑嗪组失眠或噩梦的发生率较低(3.3% vs. 20.7%,P = 0.039),但直立性低血压的发生率较高(16.7% vs. 0%,P = 0.007)。正性低血压的严重程度为轻度至中度:结论:小剂量哌唑嗪能有效改善抑郁症和外伤史患者的情绪症状,常见的不良反应为轻中度正张性低血压:临床试验注册:ChiCTR2200063642。
{"title":"Augmentation with prazosin for patients with depression and a history of trauma: A randomised, double-blind, placebo-controlled study.","authors":"Ping Guo, Yong Xu, Liang Lv, Min Feng, Yu Fang, Shanfei Cheng, Xiaoqing Xiao, Juanjuan Huang, Wei Sheng, Shikai Wang, Huanxin Chen","doi":"10.1111/acps.13763","DOIUrl":"https://doi.org/10.1111/acps.13763","url":null,"abstract":"<p><strong>Introduction: </strong>Depression with a history of trauma often responds poorly to conventional antidepressants and has a poor prognosis. Prazosin, an α1-adrenoceptor blocker, has shown promise in treating post-traumatic stress disorder symptoms, particularly nightmares. Its potential in treating depression with trauma history warrants investigation.</p><p><strong>Aims of the study: </strong>This randomised, double-blind, placebo-controlled study aimed to investigate the efficacy and tolerability of low-dose prazosin (0.5-1 mg/day) as an augmentation strategy in patients with depression and a history of trauma. We sought to determine if prazosin could provide rapid symptom improvement and enhance overall treatment response compared to placebo in this difficult-to-treat patient population.</p><p><strong>Methods: </strong>This randomised, double-blind, placebo-controlled clinical study included 59 patients with first-episode or recurrent unipolar or bipolar depression. After basic antidepressant treatment, they were randomly assigned to a prazosin (0.5-1 mg/day) or placebo group for a 6-week double-blind controlled study. The Montgomery-Åsberg Depression Rating Scale, 17-item Hamilton Depression Scale (HAMD-17), and Hamilton Anxiety Scale (HAMA) were used to evaluate efficacy.</p><p><strong>Results: </strong>There were no significant differences in the results of the demographic and clinical symptom assessment between the two groups (p > 0.05). The difference between the HAMD-17 and HAMA scores was statistically significant after 3 days of treatment (p < 0.05). The difference in response rate between the two groups was statistically significant after week 4 of treatment (end of week 4, 56.7% vs. 24.1%, p = 0.011; end of week 6, 80.0% vs. 48.3%, p = 0.011). The incidence of adverse reactions in the prazosin and placebo groups was 20.0% and 24.1%, respectively, with no statistically significant differences (p > 0.05); however, the prazosin group had a lower incidence of sleeplessness or nightmares (3.3% vs. 20.7%, p = 0.039) but a higher incidence of orthostatic hypotension (16.7% vs. 0%, p = 0.007). The severity of orthostatic hypotension was mild to moderate.</p><p><strong>Conclusion: </strong>Low-dose prazosin can effectively improve the emotional symptoms of patients with depression and a history of trauma, and the common adverse reaction is mild-to-moderate orthostatic hypotension.</p><p><strong>Clinical trial registration: </strong>ChiCTR2200063642.</p>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142337540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prediction of suicide attempt in a Swedish population-based cohort. 瑞典人群自杀未遂的预测。
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-09-24 DOI: 10.1111/acps.13761
Séverine Lannoy, Henrik Ohlsson, Mallory Stephenson, Kenneth S Kendler, Jan Sundquist, Kristina Sundquist, Alexis C Edwards

Background: Suicidal behaviors are prevalent public health concerns, and we need to improve our predictive ability to better inform prevention efforts.

Methods: Using nationwide longitudinal Swedish registers, we included 344,490 males and 323,177 females born 1982-1990 with information on genetic liability and environmental exposures from birth to age 16: perinatal variables, parental psychopathology (suicide attempt, substance use disorder, major depression), family status, socioeconomic difficulties, peers' psychopathology, and school grades. We conducted sex-specific analysis and developed data-driven predictive models including risk factors that occurred between ages 0 and 16 using structural equation modeling.

Results: In both females and males, the best-fitting models reveal a complex risk pathway to suicide attempt. In females, the model indicates four direct effects on suicide attempt risk: the occurrence of suicide attempt in parents during childhood (β = 0.159, 95% CI: 0.118; 0.199) and adolescence (β = 0.115, 95% CI: 0.077; 0.153), suicide attempt in peers (β = 0.068, 95% CI: 0.057; 0.079), and low academic achievement (β = 0.166, 95% CI: 0.156; 0.175). In males, aggregate genetic liability for suicide attempt (β = 0.130, 95% CI: 0.111; 0.148), suicide attempt in parents during adolescence (β = 0.099, 95% CI: 0.074; 0.124), suicide attempt in peers (β = 0.118, 95% CI: 0.108; 0.129), and low academic achievement (β = 0.61, 95% CI: 0.152; 0.171) were related to later suicide attempt. These factors also acted as mediators to explain the association between environmental exposures in childhood and later suicide attempt.

Conclusions: These findings illustrate sex-specific pathways to suicide attempt by including risk factors that occur during the development. Results highlight the importance of genetic and family environment but also the prominent role of academic achievement.

背景:自杀行为是普遍存在的公共卫生问题,我们需要提高预测能力,以便更好地开展预防工作:通过瑞典全国范围内的纵向登记,我们纳入了 344,490 名男性和 323,177 名女性,他们出生于 1982-1990 年,从出生到 16 岁期间的遗传责任和环境暴露信息包括:围产期变量、父母精神病理学(自杀未遂、药物使用障碍、重度抑郁症)、家庭状况、社会经济困难、同龄人精神病理学和学校成绩。我们针对不同性别进行了分析,并利用结构方程模型建立了数据驱动的预测模型,其中包括发生在 0 至 16 岁之间的风险因素:在女性和男性中,最佳拟合模型揭示了自杀未遂的复杂风险途径。在女性中,该模型显示了对自杀未遂风险的四种直接影响:童年时期(β = 0.159,95% CI:0.118;0.199)和青春期(β = 0.115,95% CI:0.077;0.153)父母自杀未遂、同龄人自杀未遂(β = 0.068,95% CI:0.057;0.079)和学习成绩差(β = 0.166,95% CI:0.156;0.175)。在男性中,自杀未遂的总体遗传责任(β = 0.130,95% CI:0.111;0.148)、青春期父母的自杀未遂(β = 0.099,95% CI:0.074;0.124)、同伴的自杀未遂(β = 0.118,95% CI:0.108;0.129)和学习成绩差(β = 0.61,95% CI:0.152;0.171)与后来的自杀未遂有关。这些因素也是解释童年环境暴露与日后自杀未遂之间关系的中介因素:这些研究结果说明了自杀企图的性别特异性途径,其中包括在成长过程中出现的风险因素。研究结果凸显了遗传和家庭环境的重要性,以及学业成绩的突出作用。
{"title":"Prediction of suicide attempt in a Swedish population-based cohort.","authors":"Séverine Lannoy, Henrik Ohlsson, Mallory Stephenson, Kenneth S Kendler, Jan Sundquist, Kristina Sundquist, Alexis C Edwards","doi":"10.1111/acps.13761","DOIUrl":"https://doi.org/10.1111/acps.13761","url":null,"abstract":"<p><strong>Background: </strong>Suicidal behaviors are prevalent public health concerns, and we need to improve our predictive ability to better inform prevention efforts.</p><p><strong>Methods: </strong>Using nationwide longitudinal Swedish registers, we included 344,490 males and 323,177 females born 1982-1990 with information on genetic liability and environmental exposures from birth to age 16: perinatal variables, parental psychopathology (suicide attempt, substance use disorder, major depression), family status, socioeconomic difficulties, peers' psychopathology, and school grades. We conducted sex-specific analysis and developed data-driven predictive models including risk factors that occurred between ages 0 and 16 using structural equation modeling.</p><p><strong>Results: </strong>In both females and males, the best-fitting models reveal a complex risk pathway to suicide attempt. In females, the model indicates four direct effects on suicide attempt risk: the occurrence of suicide attempt in parents during childhood (β = 0.159, 95% CI: 0.118; 0.199) and adolescence (β = 0.115, 95% CI: 0.077; 0.153), suicide attempt in peers (β = 0.068, 95% CI: 0.057; 0.079), and low academic achievement (β = 0.166, 95% CI: 0.156; 0.175). In males, aggregate genetic liability for suicide attempt (β = 0.130, 95% CI: 0.111; 0.148), suicide attempt in parents during adolescence (β = 0.099, 95% CI: 0.074; 0.124), suicide attempt in peers (β = 0.118, 95% CI: 0.108; 0.129), and low academic achievement (β = 0.61, 95% CI: 0.152; 0.171) were related to later suicide attempt. These factors also acted as mediators to explain the association between environmental exposures in childhood and later suicide attempt.</p><p><strong>Conclusions: </strong>These findings illustrate sex-specific pathways to suicide attempt by including risk factors that occur during the development. Results highlight the importance of genetic and family environment but also the prominent role of academic achievement.</p>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142306681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psychosis Prognosis Predictor: A continuous and uncertainty‐aware prediction of treatment outcome in first‐episode psychosis 精神病预后预测器:对首发精神病治疗结果的连续性和不确定性预测
IF 6.7 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-09-19 DOI: 10.1111/acps.13754
Daniël P. J. van Opstal, Seyed Mostafa Kia, Lea Jakob, Metten Somers, Iris E. C. Sommer, Inge Winter‐van Rossum, René S. Kahn, Wiepke Cahn, Hugo G. Schnack
IntroductionMachine learning models have shown promising potential in individual‐level outcome prediction for patients with psychosis, but also have several limitations. To address some of these limitations, we present a model that predicts multiple outcomes, based on longitudinal patient data, while integrating prediction uncertainty to facilitate more reliable clinical decision‐making.Material and MethodsWe devised a recurrent neural network architecture incorporating long short‐term memory (LSTM) units to facilitate outcome prediction by leveraging multimodal baseline variables and clinical data collected at multiple time points. To account for model uncertainty, we employed a novel fuzzy logic approach to integrate the level of uncertainty into individual predictions. We predicted antipsychotic treatment outcomes in 446 first‐episode psychosis patients in the OPTiMiSE study, for six different clinical scenarios. The treatment outcome measures assessed at both week 4 and week 10 encompassed symptomatic remission, clinical global remission, and functional remission.ResultsUsing only baseline predictors to predict different outcomes at week 4, leave‐one‐site‐out validation AUC ranged from 0.62 to 0.66; performance improved when clinical data from week 1 was added (AUC = 0.66–0.71). For outcome at week 10, using only baseline variables, the models achieved AUC = 0.56–0.64; using data from more time points (weeks 1, 4, and 6) improved the performance to AUC = 0.72–0.74. After incorporating prediction uncertainties and stratifying the model decisions based on model confidence, we could achieve accuracies above 0.8 for ~50% of patients in five out of the six clinical scenarios.ConclusionWe constructed prediction models utilizing a recurrent neural network architecture tailored to clinical scenarios derived from a time series dataset. One crucial aspect we incorporated was the consideration of uncertainty in individual predictions, which enhances the reliability of decision‐making based on the model's output. We provided evidence showcasing the significance of leveraging time series data for achieving more accurate treatment outcome prediction in the field of psychiatry.
导言机器学习模型在精神病患者的个体水平结果预测方面显示出了巨大的潜力,但也存在一些局限性。为了解决其中的一些局限性,我们提出了一种基于患者纵向数据预测多种结果的模型,同时整合了预测的不确定性,以促进更可靠的临床决策。 材料与方法 我们设计了一种包含长短期记忆(LSTM)单元的递归神经网络架构,通过利用在多个时间点收集的多模态基线变量和临床数据来促进结果预测。为了考虑模型的不确定性,我们采用了一种新颖的模糊逻辑方法,将不确定性水平整合到单个预测中。在 OPTiMiSE 研究中,我们针对六种不同的临床情况,对 446 名首发精神病患者的抗精神病治疗结果进行了预测。在第4周和第10周评估的治疗结果包括症状缓解、临床总体缓解和功能缓解。结果仅使用基线预测因子预测第4周的不同结果,leave-one-site-out验证的AUC从0.62到0.66不等;当加入第1周的临床数据时,性能有所提高(AUC = 0.66-0.71)。对于第 10 周的结果,仅使用基线变量,模型的 AUC = 0.56-0.64;使用更多时间点(第 1、4 和 6 周)的数据后,性能提高到 AUC = 0.72-0.74。在纳入预测不确定性并根据模型置信度对模型决策进行分层后,我们可以在六种临床方案中的五种方案中使约 50% 的患者的准确率达到 0.8 以上。我们纳入的一个重要方面是考虑了单个预测中的不确定性,从而提高了根据模型输出做出决策的可靠性。我们提供的证据表明,利用时间序列数据在精神病学领域实现更准确的治疗结果预测具有重要意义。
{"title":"Psychosis Prognosis Predictor: A continuous and uncertainty‐aware prediction of treatment outcome in first‐episode psychosis","authors":"Daniël P. J. van Opstal, Seyed Mostafa Kia, Lea Jakob, Metten Somers, Iris E. C. Sommer, Inge Winter‐van Rossum, René S. Kahn, Wiepke Cahn, Hugo G. Schnack","doi":"10.1111/acps.13754","DOIUrl":"https://doi.org/10.1111/acps.13754","url":null,"abstract":"IntroductionMachine learning models have shown promising potential in individual‐level outcome prediction for patients with psychosis, but also have several limitations. To address some of these limitations, we present a model that predicts multiple outcomes, based on longitudinal patient data, while integrating prediction uncertainty to facilitate more reliable clinical decision‐making.Material and MethodsWe devised a recurrent neural network architecture incorporating long short‐term memory (LSTM) units to facilitate outcome prediction by leveraging multimodal baseline variables and clinical data collected at multiple time points. To account for model uncertainty, we employed a novel fuzzy logic approach to integrate the level of uncertainty into individual predictions. We predicted antipsychotic treatment outcomes in 446 first‐episode psychosis patients in the OPTiMiSE study, for six different clinical scenarios. The treatment outcome measures assessed at both week 4 and week 10 encompassed symptomatic remission, clinical global remission, and functional remission.ResultsUsing only baseline predictors to predict different outcomes at week 4, leave‐one‐site‐out validation AUC ranged from 0.62 to 0.66; performance improved when clinical data from week 1 was added (AUC = 0.66–0.71). For outcome at week 10, using only baseline variables, the models achieved AUC = 0.56–0.64; using data from more time points (weeks 1, 4, and 6) improved the performance to AUC = 0.72–0.74. After incorporating prediction uncertainties and stratifying the model decisions based on model confidence, we could achieve accuracies above 0.8 for ~50% of patients in five out of the six clinical scenarios.ConclusionWe constructed prediction models utilizing a recurrent neural network architecture tailored to clinical scenarios derived from a time series dataset. One crucial aspect we incorporated was the consideration of uncertainty in individual predictions, which enhances the reliability of decision‐making based on the model's output. We provided evidence showcasing the significance of leveraging time series data for achieving more accurate treatment outcome prediction in the field of psychiatry.","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":"18 1","pages":""},"PeriodicalIF":6.7,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142255816","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of weight gain on antipsychotic nonadherence or discontinuation: A systematic review and meta‐analysis 体重增加对不服用或停用抗精神病药物的影响:系统回顾和荟萃分析
IF 6.7 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-09-17 DOI: 10.1111/acps.13758
Riddhita De, Emily C. C. Smith, Janani Navagnanavel, Emily Au, Kateryna Maksyutynska, Maria Papoulias, Raghunath Singh, Kristoffer J. Panganiban, Bailey Humber, Grimur Høgnason Mohr, Mette Ødegaard Nielsen, Bjørn H. Ebdrup, Gary Remington, Sri Mahavir Agarwal, Margaret K. Hahn
BackgroundNonadherence/discontinuation of antipsychotic (AP) medications represents an important clinical issue in patients across psychiatric disorders, including schizophrenia spectrum disorders (SSDs). While antipsychotic‐induced weight gain (AIWG) is a reported contributor to nonadherence, a systematic review of the association between AIWG and medication nonadherence/discontinuation has not been explored previously.MethodA systematic search was conducted in MEDLINE, EMBASE, PsychINFO, CINAHL, and CENTRAL databases, among others, to help identify all studies which explored adherence, study dropouts, AP switching and/or discontinuations attributable to AIWG among individuals with severe mental illness. A meta‐analysis was also completed where applicable.ResultsWe identified two categories of studies for the meta‐analysis. Category 1 included three studies, which compared measures of AP adherence or discontinuation across BMI classes/degrees of self‐reported weight gain. When compared to normal weight individuals receiving APs or those who did not report AIWG, individuals who were either overweight or obese or reported weight gain in relation to AP use had an increased odds of AP nonadherence (OR 2.37; 95% CI 1.51–3.73; p = 0.0002). Category 2 had 14 studies which compared measures of discontinuation related to weight gain reported as an adverse effect across different APs. Olanzapine was associated with a 3.32 times (95% CI 2.32–4.74; p < 0.00001) increased likelihood of nonadherence or discontinuation when compared to other APs with lower weight gain liabilities. Similarly, APs with moderate weight gain liability (paliperidone, risperidone, and quetiapine) increased the odds of nonadherence or discontinuation by 2.25 (95% CI 1.31–3.87; p = 0.003) when compared to APs considered to have lower weight gain liability (i.e. haloperidol and aripiprazole). The qualitative summary also confirmed these findings.ConclusionThis review and meta‐analysis suggests that AIWG influences medication nonadherence/discontinuation, whereby APs with higher weight gain liability are associated with nonadherence/discontinuation. Additional studies are needed to confirm these findings.
背景抗精神病药物(AP)的不依从/停药是包括精神分裂症谱系障碍(SSD)在内的各种精神疾病患者的一个重要临床问题。方法 在MEDLINE、EMBASE、PsychINFO、CINAHL和CENTRAL等数据库中进行了系统检索,以帮助确定所有探讨严重精神疾病患者因AIWG而导致的依从性、研究辍学、抗精神病药物转换和/或停药的研究。在适用的情况下,我们还完成了一项荟萃分析。结果我们为荟萃分析确定了两类研究。第一类包括三项研究,这些研究比较了不同 BMI 等级/自我报告体重增加程度的 AP 依从性或停药情况。与接受 AP 或未报告 AIWG 的正常体重者相比,超重或肥胖或报告体重增加与 AP 使用有关的人不坚持 AP 的几率更高(OR 2.37;95% CI 1.51-3.73;P = 0.0002)。第 2 类共有 14 项研究,这些研究比较了与不同 APs 的不良反应体重增加有关的停药措施。与体重增加责任较低的其他 APs 相比,奥氮平导致不依从或停药的可能性增加了 3.32 倍 (95% CI 2.32-4.74; p < 0.00001)。同样,与被认为具有较低体重增加责任的 APs(即氟哌啶醇和阿立哌唑)相比,具有中等体重增加责任的 APs(帕潘利酮、利培酮和喹硫平)使不依从或停药的几率增加了 2.25 (95% CI 1.31-3.87; p = 0.003)。结论本综述和荟萃分析表明,AIWG 会影响药物的不依从性/停药,其中体重增加责任较高的 APs 与不依从性/停药相关。还需要更多的研究来证实这些发现。
{"title":"The impact of weight gain on antipsychotic nonadherence or discontinuation: A systematic review and meta‐analysis","authors":"Riddhita De, Emily C. C. Smith, Janani Navagnanavel, Emily Au, Kateryna Maksyutynska, Maria Papoulias, Raghunath Singh, Kristoffer J. Panganiban, Bailey Humber, Grimur Høgnason Mohr, Mette Ødegaard Nielsen, Bjørn H. Ebdrup, Gary Remington, Sri Mahavir Agarwal, Margaret K. Hahn","doi":"10.1111/acps.13758","DOIUrl":"https://doi.org/10.1111/acps.13758","url":null,"abstract":"BackgroundNonadherence/discontinuation of antipsychotic (AP) medications represents an important clinical issue in patients across psychiatric disorders, including schizophrenia spectrum disorders (SSDs). While antipsychotic‐induced weight gain (AIWG) is a reported contributor to nonadherence, a systematic review of the association between AIWG and medication nonadherence/discontinuation has not been explored previously.MethodA systematic search was conducted in MEDLINE, EMBASE, PsychINFO, CINAHL, and CENTRAL databases, among others, to help identify all studies which explored adherence, study dropouts, AP switching and/or discontinuations attributable to AIWG among individuals with severe mental illness. A meta‐analysis was also completed where applicable.ResultsWe identified two categories of studies for the meta‐analysis. Category 1 included three studies, which compared measures of AP adherence or discontinuation across BMI classes/degrees of self‐reported weight gain. When compared to normal weight individuals receiving APs or those who did not report AIWG, individuals who were either overweight or obese or reported weight gain in relation to AP use had an increased odds of AP nonadherence (OR 2.37; 95% CI 1.51–3.73; <jats:italic>p</jats:italic> = 0.0002). Category 2 had 14 studies which compared measures of discontinuation related to weight gain reported as an adverse effect across different APs. Olanzapine was associated with a 3.32 times (95% CI 2.32–4.74; <jats:italic>p</jats:italic> &lt; 0.00001) increased likelihood of nonadherence or discontinuation when compared to other APs with lower weight gain liabilities. Similarly, APs with moderate weight gain liability (paliperidone, risperidone, and quetiapine) increased the odds of nonadherence or discontinuation by 2.25 (95% CI 1.31–3.87; <jats:italic>p</jats:italic> = 0.003) when compared to APs considered to have lower weight gain liability (i.e. haloperidol and aripiprazole). The qualitative summary also confirmed these findings.ConclusionThis review and meta‐analysis suggests that AIWG influences medication nonadherence/discontinuation, whereby APs with higher weight gain liability are associated with nonadherence/discontinuation. Additional studies are needed to confirm these findings.","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":"42 1","pages":""},"PeriodicalIF":6.7,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142256090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A national evaluation of a multi‐modal, blended, digital intervention integrated within Australian youth mental health services 对纳入澳大利亚青少年心理健康服务的多模式混合数字干预措施进行全国性评估
IF 6.7 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-09-12 DOI: 10.1111/acps.13751
M. Alvarez‐Jimenez, J. Nicholas, L. Valentine, P. Liu, S. Mangelsdorf, S. Baker, T. Gilbertson, G. O'Loughlin, C. McEnery, P. D. McGorry, J. F. Gleeson, S. P. Cross
BackgroundYouth mental health (YMH) services have been established internationally to provide timely, age‐appropriate, mental health treatment and improve long‐term outcomes. However, YMH services face challenges including long waiting times, limited continuity of care, and time‐bound support. To bridge this gap, MOST was developed as a scalable, blended, multi‐modal digital platform integrating real‐time and asynchronous clinician‐delivered counselling; interactive psychotherapeutic content; vocational support; peer support, and a youth‐focused online community. The implementation of MOST within Australian YMH services has been publicly funded.ObjectiveThe primary aim of this study was to evaluate the real‐world engagement, outcomes, and experience of MOST during the first 32 months of implementation.MethodYoung people from participating YMH services were referred into MOST. Engagement metrics were derived from platform usage. Symptom and satisfaction measures were collected at baseline, 6, and 12 (primary endpoint) weeks. Effect sizes were calculated for the primary outcomes of depression and anxiety and secondary outcomes of psychological distress and wellbeing.ResultsFive thousand seven hundred and two young people from 262 clinics signed up and used MOST at least once. Young people had an average of 19 login sessions totalling 129 min over the first 12 weeks of use, with 71.7% using MOST for at least 14 days, 40.1% for 12 weeks, and 18.8% for 24 weeks. There was a statistically significant, moderate improvement in depression and anxiety at 12 weeks as measured by the PHQ4 across all users irrespective of treatment stage (d = 0.41, 95% CI 0.35–0.46). Satisfaction levels were high, with 93% recommending MOST to a friend. One thousand one hundred and eighteen young people provided written feedback, of which 68% was positive and 31% suggested improvement.ConclusionsMOST is a highly promising blended digital intervention with potential to address the limitations and enhance the impact of YMH services.
背景国际上已经建立了青少年心理健康(YMH)服务,以提供及时、适龄的心理健康治疗,并改善长期疗效。然而,青少年心理健康服务面临着各种挑战,包括等待时间长、护理的连续性有限以及有时限的支持。为了弥补这一差距,MOST 被开发成一个可扩展的、混合的、多模式的数字平台,整合了临床医生提供的实时和异步咨询、互动式心理治疗内容、职业支持、同伴支持以及一个以青少年为中心的在线社区。这项研究的主要目的是评估社会变革管理计划实施 32 个月来的实际参与情况、成果和体验。参与度指标来自平台使用情况。在基线、6周和12周(主要终点)收集症状和满意度指标。结果来自 262 家诊所的 5702 名年轻人注册并至少使用了一次 MOST。在使用的前 12 周内,年轻人平均登录了 19 次,总计 129 分钟,其中 71.7% 的人至少使用了 14 天,40.1% 的人使用了 12 周,18.8% 的人使用了 24 周。根据PHQ4的测量结果,无论治疗阶段如何,所有用户在12周时的抑郁和焦虑情况都有了明显的改善(d = 0.41,95% CI 0.35-0.46)。满意度很高,93%的人向朋友推荐社会变革管理计划。118名青少年提供了书面反馈,其中68%为正面反馈,31%建议改进。
{"title":"A national evaluation of a multi‐modal, blended, digital intervention integrated within Australian youth mental health services","authors":"M. Alvarez‐Jimenez, J. Nicholas, L. Valentine, P. Liu, S. Mangelsdorf, S. Baker, T. Gilbertson, G. O'Loughlin, C. McEnery, P. D. McGorry, J. F. Gleeson, S. P. Cross","doi":"10.1111/acps.13751","DOIUrl":"https://doi.org/10.1111/acps.13751","url":null,"abstract":"BackgroundYouth mental health (YMH) services have been established internationally to provide timely, age‐appropriate, mental health treatment and improve long‐term outcomes. However, YMH services face challenges including long waiting times, limited continuity of care, and time‐bound support. To bridge this gap, MOST was developed as a scalable, blended, multi‐modal digital platform integrating real‐time and asynchronous clinician‐delivered counselling; interactive psychotherapeutic content; vocational support; peer support, and a youth‐focused online community. The implementation of MOST within Australian YMH services has been publicly funded.ObjectiveThe primary aim of this study was to evaluate the real‐world engagement, outcomes, and experience of MOST during the first 32 months of implementation.MethodYoung people from participating YMH services were referred into MOST. Engagement metrics were derived from platform usage. Symptom and satisfaction measures were collected at baseline, 6, and 12 (primary endpoint) weeks. Effect sizes were calculated for the primary outcomes of depression and anxiety and secondary outcomes of psychological distress and wellbeing.ResultsFive thousand seven hundred and two young people from 262 clinics signed up and used MOST at least once. Young people had an average of 19 login sessions totalling 129 min over the first 12 weeks of use, with 71.7% using MOST for at least 14 days, 40.1% for 12 weeks, and 18.8% for 24 weeks. There was a statistically significant, moderate improvement in depression and anxiety at 12 weeks as measured by the PHQ4 across all users irrespective of treatment stage (<jats:italic>d</jats:italic> = 0.41, 95% CI 0.35–0.46). Satisfaction levels were high, with 93% recommending MOST to a friend. One thousand one hundred and eighteen young people provided written feedback, of which 68% was positive and 31% suggested improvement.ConclusionsMOST is a highly promising blended digital intervention with potential to address the limitations and enhance the impact of YMH services.","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":"73 1","pages":""},"PeriodicalIF":6.7,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142222105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationship between nonexercise activity and mood in patients with eating disorders. 饮食失调症患者的非运动活动与情绪之间的关系。
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-09-07 DOI: 10.1111/acps.13757
Robin Olfermann, Sabine Schlegel, Anna Vogelsang, Ulrich Ebner-Priemer, Almut Zeeck, Markus Reichert

Introduction: Many patients with eating disorders (EDs) engage in excessive and compulsive physical activity (pathological exercise, PE) to regulate negative mood or to "burn calories." PE can lead to negative health consequences. Non-exercise activity (NEA) bears the potential to serve as intervention target to counteract PE and problematic eating behaviors since it has been associated with positive mood effects. However, to date, there is no investigation on whether the positive link between NEA and mood seen in the healthy translates to patients with ED.

Material and methods: To study potential associations of NEA and mood in ED, we subjected 29 ED-patients and 35 healthy controls (HCs) to an ambulatory assessment study across 7 days. We measured NEA via accelerometers and repeatedly assessed mood on electronic smartphone diaries via a mixed sampling strategy based on events, activity and time. Within- and between-subject effects of NEA on mood, PE as moderator, and the temporal course of effects were analyzed via multilevel modeling.

Results: NEA increased valence (β = 2.12, p < 0.001) and energetic arousal (β = 4.02, p < 0.001) but showed no significant effect on calmness. The effects of NEA on energetic arousal where significantly stronger for HCs (βHC = 6.26, p < 0.001) than for EDs (βED = 4.02, p < 0.001; βinteraction = 2.24, p = 0.0135). Effects of NEA were robust across most timeframes of NEA and significantly moderated by PE, that is, Lower PE levels exhibited stronger NEA effects on energetic arousal.

Conclusion: Patients with ED and HC show an affective benefit from NEA, partly depending on the level of PE. If replicated in experimental daily life studies, this evidence may pave the way towards expedient NEA interventions to cope with negative mood. Interventions could be especially promising if delivered as Just-in-time adaptive interventions (JITAIs) and should be tailored according to the PE level.

导言:许多饮食失调症(EDs)患者为了调节负面情绪或 "燃烧卡路里",会进行过度和强迫性的体育锻炼(病理性锻炼,PE)。病理性运动会对健康造成负面影响。由于非运动性活动(NEA)与积极情绪效应相关,因此有可能成为抵制 PE 和问题饮食行为的干预目标。然而,迄今为止,尚无研究表明,健康人的 NEA 与情绪之间的积极联系是否也适用于 ED 患者:为了研究 NEA 与 ED 患者情绪之间的潜在联系,我们对 29 名 ED 患者和 35 名健康对照者(HCs)进行了为期 7 天的流动评估研究。我们通过加速度计测量NEA,并通过基于事件、活动和时间的混合采样策略,在电子智能手机日记上反复评估情绪。通过多层次建模分析了NEA对情绪的受试者内和受试者间效应、作为调节因素的PE以及效应的时间过程:NEA 增加了情绪(β = 2.12,p HC = 6.26,p ED = 4.02,p 交互作用 = 2.24,p = 0.0135)。NEA的效应在NEA的大多数时间范围内都是稳健的,并受到PE的显著调节,即较低的PE水平表现出较强的NEA对精力唤醒的效应:结论:ED和HC患者可从NEA中获得情感益处,部分取决于PE水平。如果在日常生活实验研究中得到证实,这一证据可能会为采取便捷的 NEA 干预措施来应对负面情绪铺平道路。如果以适时适应性干预(JITAIs)的方式进行干预,并根据 PE 水平量身定制干预方案,则会特别有前景。
{"title":"Relationship between nonexercise activity and mood in patients with eating disorders.","authors":"Robin Olfermann, Sabine Schlegel, Anna Vogelsang, Ulrich Ebner-Priemer, Almut Zeeck, Markus Reichert","doi":"10.1111/acps.13757","DOIUrl":"https://doi.org/10.1111/acps.13757","url":null,"abstract":"<p><strong>Introduction: </strong>Many patients with eating disorders (EDs) engage in excessive and compulsive physical activity (pathological exercise, PE) to regulate negative mood or to \"burn calories.\" PE can lead to negative health consequences. Non-exercise activity (NEA) bears the potential to serve as intervention target to counteract PE and problematic eating behaviors since it has been associated with positive mood effects. However, to date, there is no investigation on whether the positive link between NEA and mood seen in the healthy translates to patients with ED.</p><p><strong>Material and methods: </strong>To study potential associations of NEA and mood in ED, we subjected 29 ED-patients and 35 healthy controls (HCs) to an ambulatory assessment study across 7 days. We measured NEA via accelerometers and repeatedly assessed mood on electronic smartphone diaries via a mixed sampling strategy based on events, activity and time. Within- and between-subject effects of NEA on mood, PE as moderator, and the temporal course of effects were analyzed via multilevel modeling.</p><p><strong>Results: </strong>NEA increased valence (β = 2.12, p < 0.001) and energetic arousal (β = 4.02, p < 0.001) but showed no significant effect on calmness. The effects of NEA on energetic arousal where significantly stronger for HCs (β<sub>HC</sub> = 6.26, p < 0.001) than for EDs (β<sub>ED</sub> = 4.02, p < 0.001; β<sub>interaction</sub> = 2.24, p = 0.0135). Effects of NEA were robust across most timeframes of NEA and significantly moderated by PE, that is, Lower PE levels exhibited stronger NEA effects on energetic arousal.</p><p><strong>Conclusion: </strong>Patients with ED and HC show an affective benefit from NEA, partly depending on the level of PE. If replicated in experimental daily life studies, this evidence may pave the way towards expedient NEA interventions to cope with negative mood. Interventions could be especially promising if delivered as Just-in-time adaptive interventions (JITAIs) and should be tailored according to the PE level.</p>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142144552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of sex in the effectiveness of functional remediation in bipolar disorder 性别对双相情感障碍功能性矫正效果的影响。
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-09-07 DOI: 10.1111/acps.13748
Maria Serra-Navarro, Derek Clougher, Brisa Solé, Jose Sánchez-Moreno, Ana González-Pinto, Esther Jiménez, Benedikt L. Amann, Vicent Balanzá-Martínez, Rafael Tabarés-Seisdedos, Celso Arango, Vivian Accardo, María Paz García-Portilla, Ángela Ibáñez, José Manuel Crespo, José Luis Ayuso-Mateos, Silvia Amoretti, Carla Torrent, Anabel Martínez-Aran, Eduard Vieta, CIBERSAM Functional Remediation Group

Background

Functional recovery remains a core clinical objective for patients with bipolar disorder (BD). Sociodemographic, clinical, and neurocognitive variables are associated with long-term functional impairment, yet the impact of sex differences is unclear. Functional remediation (FR) is a validated intervention aimed at achieving functional recovery in BD. The present study assessed the effect of sex differences of FR on psychosocial functioning at post-treatment (6-months) and 12-month follow-up (FUP). To the best of our knowledge, this is the first study to explore the role of sex as a factor in the efficacy of FR.

Methods

157 participants with BD were randomly assigned to either FR (N = 77) or treatment as usual group (80). Clinical, sociodemographic, neuropsychological, and functional data were obtained using a comprehensive assessment battery. Sex differences were explored via a general linear model (GLM) for repeated measures to compare the effect of sex on the intervention over time (6 months and FUP).

Results

Results demonstrated that FR benefits both sexes, males (p = 0.001; d’ = 0.88) and females (p = 0.04; d’ = 0.57), at 6 months suggesting a generalized functional improvement. Conversely, at 12-month FUP sex differences were observed only in males (p = 0.005; d’ = 0.68).

Conclusions

FR is a beneficial intervention for males and females after treatment, suggesting that there are no relevant distinct needs. Females may benefit from ongoing psychosocial functioning booster sessions after the intervention to maintain original improvements. Future research exploring sex differences could help to identify strategies to offer personalized FR intervention approaches in individuals with BD.

背景:功能恢复仍是双相情感障碍(BD)患者的核心临床目标。社会人口学、临床和神经认知变量与长期功能障碍有关,但性别差异的影响尚不明确。功能性补救(FR)是一种有效的干预措施,旨在实现双相情感障碍患者的功能恢复。本研究评估了性别差异对治疗后(6 个月)和 12 个月随访(FUP)期间心理社会功能的影响。方法:157 名 BD 患者被随机分配到 FR 组(77 人)或常规治疗组(80 人)。使用综合评估电池获取临床、社会人口学、神经心理学和功能数据。通过重复测量的一般线性模型(GLM)探讨了性别差异,以比较性别在不同时间(6 个月和家庭综合评估)对干预的影响:结果表明,在 6 个月时,FR 对男性(p = 0.001;d' = 0.88)和女性(p = 0.04;d' = 0.57)都有益处,表明功能得到了普遍改善。相反,在为期 12 个月的功能障碍评估中,仅在男性中观察到性别差异(p = 0.005;d' = 0.68):结论:FR 在治疗后对男性和女性都是一种有益的干预措施,这表明并不存在相关的不同需求。女性可能会受益于干预后持续的社会心理功能强化训练,以保持原有的改善。未来探索性别差异的研究将有助于确定为 BD 患者提供个性化 FR 干预方法的策略。
{"title":"The impact of sex in the effectiveness of functional remediation in bipolar disorder","authors":"Maria Serra-Navarro,&nbsp;Derek Clougher,&nbsp;Brisa Solé,&nbsp;Jose Sánchez-Moreno,&nbsp;Ana González-Pinto,&nbsp;Esther Jiménez,&nbsp;Benedikt L. Amann,&nbsp;Vicent Balanzá-Martínez,&nbsp;Rafael Tabarés-Seisdedos,&nbsp;Celso Arango,&nbsp;Vivian Accardo,&nbsp;María Paz García-Portilla,&nbsp;Ángela Ibáñez,&nbsp;José Manuel Crespo,&nbsp;José Luis Ayuso-Mateos,&nbsp;Silvia Amoretti,&nbsp;Carla Torrent,&nbsp;Anabel Martínez-Aran,&nbsp;Eduard Vieta,&nbsp;CIBERSAM Functional Remediation Group","doi":"10.1111/acps.13748","DOIUrl":"10.1111/acps.13748","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Functional recovery remains a core clinical objective for patients with bipolar disorder (BD). Sociodemographic, clinical, and neurocognitive variables are associated with long-term functional impairment, yet the impact of sex differences is unclear. Functional remediation (FR) is a validated intervention aimed at achieving functional recovery in BD. The present study assessed the effect of sex differences of FR on psychosocial functioning at post-treatment (6-months) and 12-month follow-up (FUP). To the best of our knowledge, this is the first study to explore the role of sex as a factor in the efficacy of FR.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>157 participants with BD were randomly assigned to either FR (<i>N</i> = 77) or treatment as usual group (80). Clinical, sociodemographic, neuropsychological, and functional data were obtained using a comprehensive assessment battery. Sex differences were explored via a general linear model (GLM) for repeated measures to compare the effect of sex on the intervention over time (6 months and FUP).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Results demonstrated that FR benefits both sexes, males (<i>p</i> = 0.001; d’ = 0.88) and females (<i>p</i> = 0.04; d’ = 0.57), at 6 months suggesting a generalized functional improvement. Conversely, at 12-month FUP sex differences were observed only in males (<i>p</i> = 0.005; d’ = 0.68).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>FR is a beneficial intervention for males and females after treatment, suggesting that there are no relevant distinct needs. Females may benefit from ongoing psychosocial functioning booster sessions after the intervention to maintain original improvements. Future research exploring sex differences could help to identify strategies to offer personalized FR intervention approaches in individuals with BD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":"150 6","pages":"543-561"},"PeriodicalIF":5.3,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142144496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Childhood maltreatment and outcomes following electroconvulsive therapy in adults with depression. 儿童时期的虐待与成年抑郁症患者接受电休克治疗后的结果。
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-09-05 DOI: 10.1111/acps.13756
Ana Jelovac, Christopher Mohan, Emma Whooley, Anna Igoe, Cathal McCaffrey, Declan M McLoughlin

Objective: Childhood maltreatment is associated with less favourable treatment outcomes with pharmacotherapy and psychotherapy for depression. It is unknown whether this increased risk of treatment resistance in maltreated individuals extends to electroconvulsive therapy (ECT).

Methods: This retrospective cohort study included 501 consecutive adult referrals for an acute course of twice-weekly ECT for unipolar or bipolar depression at an academic inpatient centre in Ireland between 2016 and 2024. Retrospectively reported physical and sexual childhood maltreatment were assessed on hospital admission. Response was defined as a score of 1 or 2 and remission was defined as a score of 1 on the Clinical Global Impression - Improvement scale 1-3 days after final ECT session. Logistic regression analyses were used to examine the associations between childhood maltreatment and ECT nonresponse and nonremission, adjusting for covariates. Mediation analyses were conducted to explore the role of psychiatric comorbidities, persistent depressive symptoms lasting 2 years or more in the current episode, and baseline depression severity.

Results: Compared to the group with no childhood maltreatment, the childhood maltreatment group had similar odds of ECT nonresponse (adjusted odds ratio = 1.47, 95% CI = 0.85-2.53) but significantly elevated odds of ECT nonremission (adjusted odds ratio = 3.75, 95% CI = 1.80-7.81). In a mediation analysis, presence of persistent depressive symptoms mediated 7.4% of the total effect of childhood maltreatment on ECT nonremission.

Conclusion: Individuals with exposure to childhood maltreatment may be less likely to achieve full remission following a course of ECT.

目的:儿童时期的虐待与抑郁症药物治疗和心理治疗的不良疗效有关。目前尚不清楚受虐待者治疗抵抗风险的增加是否也会影响到电休克疗法(ECT):这项回顾性队列研究纳入了2016年至2024年期间爱尔兰一家学术住院中心连续转诊的501名成人患者,这些患者因单相或双相抑郁症接受了每周两次的急性ECT治疗。入院时对回顾性报告的童年身体虐待和性虐待进行了评估。最后一次电疗疗程后1-3天,临床总体印象--改善量表得分达到1分即为应答,得分达到2分即为缓解。逻辑回归分析用于研究童年虐待与 ECT 无应答和无缓解之间的关系,并对协变量进行了调整。研究人员还进行了中介分析,以探讨精神疾病合并症、持续2年或更长时间的抑郁症状和基线抑郁严重程度的作用:与无童年虐待组相比,童年虐待组的电疗无反应几率相似(调整后的几率比=1.47,95% CI=0.85-2.53),但电疗无缓解几率显著升高(调整后的几率比=3.75,95% CI=1.80-7.81)。在中介分析中,持续抑郁症状的存在中介了儿童虐待对电疗无效总影响的7.4%:结论:受过童年虐待的人在接受电痉挛疗法治疗后完全缓解的可能性较小。
{"title":"Childhood maltreatment and outcomes following electroconvulsive therapy in adults with depression.","authors":"Ana Jelovac, Christopher Mohan, Emma Whooley, Anna Igoe, Cathal McCaffrey, Declan M McLoughlin","doi":"10.1111/acps.13756","DOIUrl":"https://doi.org/10.1111/acps.13756","url":null,"abstract":"<p><strong>Objective: </strong>Childhood maltreatment is associated with less favourable treatment outcomes with pharmacotherapy and psychotherapy for depression. It is unknown whether this increased risk of treatment resistance in maltreated individuals extends to electroconvulsive therapy (ECT).</p><p><strong>Methods: </strong>This retrospective cohort study included 501 consecutive adult referrals for an acute course of twice-weekly ECT for unipolar or bipolar depression at an academic inpatient centre in Ireland between 2016 and 2024. Retrospectively reported physical and sexual childhood maltreatment were assessed on hospital admission. Response was defined as a score of 1 or 2 and remission was defined as a score of 1 on the Clinical Global Impression - Improvement scale 1-3 days after final ECT session. Logistic regression analyses were used to examine the associations between childhood maltreatment and ECT nonresponse and nonremission, adjusting for covariates. Mediation analyses were conducted to explore the role of psychiatric comorbidities, persistent depressive symptoms lasting 2 years or more in the current episode, and baseline depression severity.</p><p><strong>Results: </strong>Compared to the group with no childhood maltreatment, the childhood maltreatment group had similar odds of ECT nonresponse (adjusted odds ratio = 1.47, 95% CI = 0.85-2.53) but significantly elevated odds of ECT nonremission (adjusted odds ratio = 3.75, 95% CI = 1.80-7.81). In a mediation analysis, presence of persistent depressive symptoms mediated 7.4% of the total effect of childhood maltreatment on ECT nonremission.</p><p><strong>Conclusion: </strong>Individuals with exposure to childhood maltreatment may be less likely to achieve full remission following a course of ECT.</p>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":" ","pages":""},"PeriodicalIF":5.3,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142131270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between exposure to atypical antipsychotics during pregnancy and risk of miscarriage 孕期接触非典型抗精神病药物与流产风险之间的关系。
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-09-05 DOI: 10.1111/acps.13755
Tomofumi Ishikawa, Takamasa Sakai, Noriyuki Iwama, Ryo Obara, Kei Morishita, Motohiko Adomi, Aoi Noda, Mami Ishikuro, Saya Kikuchi, Natsuko Kobayashi, Hiroaki Tomita, Masatoshi Saito, Hidekazu Nishigori, Shinichi Kuriyama, Nariyasu Mano, Taku Obara

Objective

To evaluate the association between exposure to atypical antipsychotics during pregnancy and risk of miscarriage.

Material and Methods

This nested case–control study used a large Japanese administrative database. Pregnancy onset and outcomes were estimated using previously reported algorithms, classifying cases as women becoming pregnant between 2013 and 2022 and ending in a miscarriage. Controls were randomly selected from the entire pregnancy cohort by risk-set sampling with replacement and were individually matched to the cases (3:1). The association between exposure to atypical antipsychotics and risk of miscarriage was assessed using conditional logistic regression adjusted for confounders. The association between benzodiazepine exposure and the risk of miscarriage was assessed as a positive control.

Results

In the cohort, 44,118 patients were matched with 132,317 controls. The mean ages (standard deviations) of the case and control groups were 33.3 (5.7) and 33.2 (5.5) years, respectively. The prevalence of atypical antipsychotics was 0.5% in both groups. Aripiprazole is an individual antipsychotic with the highest prescription prevalence. The adjusted odds ratios (aOR) for miscarriage were 0.966 (95% confidence interval [CI], 0.796–1.173) for atypical antipsychotics and 0.998 (0.784–1.269) for aripiprazole. A higher aOR (1.431, 95% CI 1.303–1.573) suggested an association with benzodiazepines. A sensitivity analysis that limited the population to women diagnosed with schizophrenia alone did not suggest an association between atypical antipsychotics and the risk of miscarriage.

Conclusions

The results of this study do not suggest an association between exposure to atypical antipsychotics during pregnancy and the risk of miscarriage.

目的:评估孕期接触非典型抗精神病药物与流产风险之间的关系:评估孕期接触非典型抗精神病药物与流产风险之间的关系:这项巢式病例对照研究使用了日本的大型行政数据库。妊娠起始时间和妊娠结局采用之前报道过的算法进行估计,将病例归类为在 2013 年至 2022 年期间怀孕并最终流产的女性。对照组是通过风险设置抽样从整个怀孕队列中随机抽取的,并与病例进行单独配对(3:1)。非典型抗精神病药物暴露与流产风险之间的关系采用条件逻辑回归进行评估,并对混杂因素进行了调整。苯二氮卓类药物暴露与流产风险之间的关系作为阳性对照进行评估:在队列中,44 118 名患者与 132 317 名对照者进行了配对。病例组和对照组的平均年龄(标准差)分别为 33.3(5.7)岁和 33.2(5.5)岁。两组中使用非典型抗精神病药物的比例均为 0.5%。阿立哌唑是处方率最高的一种抗精神病药物。非典型抗精神病药物的调整后流产几率(aOR)为0.966(95%置信区间[CI],0.796-1.173),阿立哌唑的调整后流产几率(aOR)为0.998(0.784-1.269)。较高的 aOR(1.431,95% CI 1.303-1.573)表明与苯二氮卓类药物有关。一项敏感性分析将研究对象限定为仅诊断出患有精神分裂症的女性,但该分析并未显示非典型抗精神病药物与流产风险之间存在关联:本研究的结果并不表明孕期接触非典型抗精神病药物与流产风险之间存在关联。
{"title":"Association between exposure to atypical antipsychotics during pregnancy and risk of miscarriage","authors":"Tomofumi Ishikawa,&nbsp;Takamasa Sakai,&nbsp;Noriyuki Iwama,&nbsp;Ryo Obara,&nbsp;Kei Morishita,&nbsp;Motohiko Adomi,&nbsp;Aoi Noda,&nbsp;Mami Ishikuro,&nbsp;Saya Kikuchi,&nbsp;Natsuko Kobayashi,&nbsp;Hiroaki Tomita,&nbsp;Masatoshi Saito,&nbsp;Hidekazu Nishigori,&nbsp;Shinichi Kuriyama,&nbsp;Nariyasu Mano,&nbsp;Taku Obara","doi":"10.1111/acps.13755","DOIUrl":"10.1111/acps.13755","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To evaluate the association between exposure to atypical antipsychotics during pregnancy and risk of miscarriage.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Material and Methods</h3>\u0000 \u0000 <p>This nested case–control study used a large Japanese administrative database. Pregnancy onset and outcomes were estimated using previously reported algorithms, classifying cases as women becoming pregnant between 2013 and 2022 and ending in a miscarriage. Controls were randomly selected from the entire pregnancy cohort by risk-set sampling with replacement and were individually matched to the cases (3:1). The association between exposure to atypical antipsychotics and risk of miscarriage was assessed using conditional logistic regression adjusted for confounders. The association between benzodiazepine exposure and the risk of miscarriage was assessed as a positive control.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In the cohort, 44,118 patients were matched with 132,317 controls. The mean ages (standard deviations) of the case and control groups were 33.3 (5.7) and 33.2 (5.5) years, respectively. The prevalence of atypical antipsychotics was 0.5% in both groups. Aripiprazole is an individual antipsychotic with the highest prescription prevalence. The adjusted odds ratios (aOR) for miscarriage were 0.966 (95% confidence interval [CI], 0.796–1.173) for atypical antipsychotics and 0.998 (0.784–1.269) for aripiprazole. A higher aOR (1.431, 95% CI 1.303–1.573) suggested an association with benzodiazepines. A sensitivity analysis that limited the population to women diagnosed with schizophrenia alone did not suggest an association between atypical antipsychotics and the risk of miscarriage.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The results of this study do not suggest an association between exposure to atypical antipsychotics during pregnancy and the risk of miscarriage.</p>\u0000 </section>\u0000 </div>","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":"150 6","pages":"562-572"},"PeriodicalIF":5.3,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142131269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Monoamine oxidase inhibitors: Seriously underused in the treatment of major depression 单胺氧化酶抑制剂:治疗重度抑郁症的药物严重不足。
IF 5.3 2区 医学 Q1 PSYCHIATRY Pub Date : 2024-09-03 DOI: 10.1111/acps.13753
Tom K. Birkenhager, Willemijn T. Heijnen
<p>Monoamine oxidase inhibitors (MAOIs) were the first licensed antidepressants, they were discovered serendipitously, during a trial of iproniazid in patients with tuberculosis in the 1950s. Iproniazid appeared to have a “psychic energizing effect,” which resulted in the improvement of depressive symptoms in some tuberculosis patients,<span><sup>1</sup></span> around that time, iproniazid was shown to inhibit the MAO enzyme. Iproniazid was approved as an antidepressant, and this led to the development of several other MAOIs. Brain neurotransmitter levels are inactivated by MAO-A (serotonin, norepinephrine, dopamine) and MAO-B (dopamine) isoenzymes. Inhibition of the MAO enzyme leads to an increasing synaptic availability of these monoamines. In addition, tranylcypromine is similar in chemical structure to amphetamine and shares its dopamine-releasing and stimulant-like effects. Tranylcypromine and phenelzine are the most frequently used non-selective MAOIs, which bind the MAO enzyme irreversibly, and deactivate it permanently. Moclobemide is a selective MAO-A inhibitor, and enters into a reversible binding to the enzyme. Tranylcypromine and Phenelzine were widely prescribed until the late 1960s. The use of MAOIs has declined dramatically, as stated in their network meta-analysis by Gimenez-Palomo et al.<span><sup>2</sup></span> The historical perspective is important in understanding this decline.</p><p>In the 1960s it was not well understood that MAOIs inhibit the breakdown of tyramine, and that excessive tyramine intake when using an MAOI, can lead to a hypertensive crisis. A series of initially unexplained hypertensive crises actually occurred, some even resulting in stroke. The cause of this “cheese reaction” was uncovered in the late 1960s, but the fear for the hypertensive reaction remained. Furthermore, in one of the first large randomized clinical trials in psychiatry,<span><sup>3</sup></span> which included 260 depressed patients, both ECT and imipramine appeared to be effective, whereas phenelzine and placebo were not. In hindsight, one may well argue, that both the duration of treatment with phenelzine (4 weeks) and its dose (maximum 60 mg daily) were insufficient, therefore, phenelzine fell short of its full efficacy potential. Subsequently, MAOIs were regarded as not very effective and dangerous antidepressant drugs. This perception influenced physicians to strongly favor tricyclic antidepressants (TCAs) over MAOIs. Usage of MAOIs further declined, following the development of newer antidepressants, especially the selective serotonin reuptake inhibitors (SSRIs). Concerns about the safety profile of MAOIs, including potentially dangerous drug–drug interactions, which could result in serotonin syndrome, and the risk of a hypertensive crisis restricted their use. Furthermore, the use of MAOIs was not promoted by any pharmaceutical company.</p><p>In several countries the number of prescriptions of MAOIs is extremely low: about 500 patie
单胺氧化酶抑制剂(MAOIs)是第一种获得许可的抗抑郁药物,是在 20 世纪 50 年代对结核病患者进行异丙嗪试验时偶然发现的。异丙嗪似乎具有 "精神振奋作用",从而改善了一些肺结核患者的抑郁症状1。异丙嗪被批准为抗抑郁药,并由此带动了其他几种 MAOIs 的开发。大脑神经递质水平会被 MAO-A(血清素、去甲肾上腺素、多巴胺)和 MAO-B(多巴胺)同工酶灭活。抑制 MAO 酶会增加这些单胺类物质在突触中的供应量。此外,氨甲环酸的化学结构与苯丙胺相似,也具有释放多巴胺和类似兴奋剂的作用。曲酰丙咪嗪和苯乙肼是最常用的非选择性 MAOIs,它们与 MAO 酶的结合是不可逆的,并使其永久失活。吗氯贝胺是一种选择性 MAO-A 抑制剂,与 MAO 酶的结合是可逆的。曲安奈德和苯乙肼在 20 世纪 60 年代末之前一直被广泛使用。正如 Gimenez-Palomo 等人在其网络荟萃分析中所述,MAOIs 的使用已急剧下降。2 历史的视角对于理解这种下降非常重要。在 20 世纪 60 年代,人们还不太了解 MAOIs 可抑制酪胺的分解,以及在使用 MAOI 时摄入过量的酪胺会导致高血压危象。一系列最初无法解释的高血压危象确实发生了,有些甚至导致了中风。这种 "奶酪反应 "的原因在 20 世纪 60 年代末被揭开,但人们对高血压反应的恐惧依然存在。此外,在精神病学最早的一项大型随机临床试验3 中,有 260 名抑郁症患者接受了治疗,其中电痉挛疗法和丙咪嗪似乎都有效,而苯乙肼和安慰剂则无效。事后看来,人们很可能会认为,苯乙肼的治疗时间(4 周)和剂量(每天最多 60 毫克)都不够,因此,苯乙肼没有充分发挥其疗效潜力。随后,MAOIs 被认为是不太有效且危险的抗抑郁药物。受这种观念的影响,医生们更加青睐三环类抗抑郁药(TCA)而非 MAOIs。随着新型抗抑郁药,尤其是选择性血清素再摄取抑制剂(SSRIs)的开发,MAOIs 的使用率进一步下降。人们担心 MAOIs 的安全性,包括可能导致血清素综合征的潜在危险的药物间相互作用,以及高血压危象的风险,这些都限制了 MAOIs 的使用。此外,任何制药公司都没有推广使用 MAOIs。在一些国家,MAOIs 的处方数量极低:在 1,600 万人口中约有 500 名患者接受了治疗。精神科住院医师从优秀的培训项目毕业时可能几乎不了解 MAOIs,不知道 MAOIs 治疗的具体适应症,也不知道如何避免这些药物的安全性问题。因此,Gimenez-Palomo 等人的全面系统综述2 强调了 MAOIs 在重度抑郁症治疗中的作用,是一项宝贵的贡献。作者认为 MAOIs 和其他抗抑郁药的抗抑郁疗效相似。然而,正如 Lee 和 Wei6 在给编辑的信中针对该系统综述所指出的,在几种亚型重度抑郁症中,MAOIs 的疗效优于其他抗抑郁药。纽约哥伦比亚大学对非典型抑郁症患者进行了六项系列研究。在非典型抑郁症患者中,苯乙肼的疗效被证明优于丙咪嗪和安慰剂。7 这六项研究包括 409 名患者,安慰剂的总体反应率为 26%,丙咪嗪为 44%,而苯乙肼为 72%。Heijnen 等人8 在一项系统综述中发现,在双相抑郁症患者中,氨甲环丙胺(40-60 毫克)的总体应答率为 74%,而对照组的应答率为 28%。他们的研究结果强调了 Thase 和 Sachs9 在上一篇综述中的观点:"在其他条件相同的情况下,MAOI 类药物氨酰环丙胺可被视为双相抑郁症的首选治疗药物。
{"title":"Monoamine oxidase inhibitors: Seriously underused in the treatment of major depression","authors":"Tom K. Birkenhager,&nbsp;Willemijn T. Heijnen","doi":"10.1111/acps.13753","DOIUrl":"10.1111/acps.13753","url":null,"abstract":"&lt;p&gt;Monoamine oxidase inhibitors (MAOIs) were the first licensed antidepressants, they were discovered serendipitously, during a trial of iproniazid in patients with tuberculosis in the 1950s. Iproniazid appeared to have a “psychic energizing effect,” which resulted in the improvement of depressive symptoms in some tuberculosis patients,&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; around that time, iproniazid was shown to inhibit the MAO enzyme. Iproniazid was approved as an antidepressant, and this led to the development of several other MAOIs. Brain neurotransmitter levels are inactivated by MAO-A (serotonin, norepinephrine, dopamine) and MAO-B (dopamine) isoenzymes. Inhibition of the MAO enzyme leads to an increasing synaptic availability of these monoamines. In addition, tranylcypromine is similar in chemical structure to amphetamine and shares its dopamine-releasing and stimulant-like effects. Tranylcypromine and phenelzine are the most frequently used non-selective MAOIs, which bind the MAO enzyme irreversibly, and deactivate it permanently. Moclobemide is a selective MAO-A inhibitor, and enters into a reversible binding to the enzyme. Tranylcypromine and Phenelzine were widely prescribed until the late 1960s. The use of MAOIs has declined dramatically, as stated in their network meta-analysis by Gimenez-Palomo et al.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; The historical perspective is important in understanding this decline.&lt;/p&gt;&lt;p&gt;In the 1960s it was not well understood that MAOIs inhibit the breakdown of tyramine, and that excessive tyramine intake when using an MAOI, can lead to a hypertensive crisis. A series of initially unexplained hypertensive crises actually occurred, some even resulting in stroke. The cause of this “cheese reaction” was uncovered in the late 1960s, but the fear for the hypertensive reaction remained. Furthermore, in one of the first large randomized clinical trials in psychiatry,&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; which included 260 depressed patients, both ECT and imipramine appeared to be effective, whereas phenelzine and placebo were not. In hindsight, one may well argue, that both the duration of treatment with phenelzine (4 weeks) and its dose (maximum 60 mg daily) were insufficient, therefore, phenelzine fell short of its full efficacy potential. Subsequently, MAOIs were regarded as not very effective and dangerous antidepressant drugs. This perception influenced physicians to strongly favor tricyclic antidepressants (TCAs) over MAOIs. Usage of MAOIs further declined, following the development of newer antidepressants, especially the selective serotonin reuptake inhibitors (SSRIs). Concerns about the safety profile of MAOIs, including potentially dangerous drug–drug interactions, which could result in serotonin syndrome, and the risk of a hypertensive crisis restricted their use. Furthermore, the use of MAOIs was not promoted by any pharmaceutical company.&lt;/p&gt;&lt;p&gt;In several countries the number of prescriptions of MAOIs is extremely low: about 500 patie","PeriodicalId":108,"journal":{"name":"Acta Psychiatrica Scandinavica","volume":"150 6","pages":"497-499"},"PeriodicalIF":5.3,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/acps.13753","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142124284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Acta Psychiatrica Scandinavica
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1